This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Osimertinib
From Proteopedia
(Difference between revisions)
(New page: <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene=''> Osimertinib, sold under the brand name Tagrisso,[4] is a medication used to treat non-small...) |
|||
| Line 1: | Line 1: | ||
<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene=''> | <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene=''> | ||
| - | Osimertinib, sold under the brand name Tagrisso,[ | + | Osimertinib, sold under the brand name Tagrisso,<ref name="a4">[https://www.who.int/medicines/publications/druginformation/INN_List113.pdf "Proposed INN: List 113"] (PDF). International Nonproprietary Names for Pharmaceutical Substances (INN). 29 (2): 285. 2015. Archived (PDF) from the original on 28 April 2017. Retrieved 16 November 2015</ref> is a medication used to treat non-small-cell lung carcinomas with specific mutations.[5][6] It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor. |
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 10:58, 9 October 2023
| |||||||||||
References
- ↑ "Proposed INN: List 113" (PDF). International Nonproprietary Names for Pharmaceutical Substances (INN). 29 (2): 285. 2015. Archived (PDF) from the original on 28 April 2017. Retrieved 16 November 2015
